Key result
Use of antiplatelet drugs in patients undergoing certain cardiovascular surgical procedures or having rapid progression of atherosclerosis may reduce thromboembolic risk.
Why the study?
Do antiplatelet drugs reduce thromboembolic risk in patients undergoing cardiovascular surgical procedures or having rapid progression of atherosclerosis?
Do antiplatelet drugs reduce thromboembolic risk in patients undergoing cardiovascular surgical procedures or having rapid progression of atherosclerosis?
Antiplatelet therapy may be beneficial in reducing thromboembolic risk in specific cardiovascular conditions and surgical procedures.
Answers are grounded in this paper and cite their sources.
May support targeted antiplatelet use in select procedures; hypothesis-generating, requiring randomized confirmation before practice change.
Platelet deposition can occur in areas of vascular damage and on prosthetic materials such as heart valves or grafts; mural thrombus formation, with eventual organization, progression to fatal occlusion, thrombolysis, or arterial embolization can follow. Use of antiplatelet drugs in patients undergoing certain cardiovascular surgical procedures or having rapid progression of atherosclerosis may reduce the thromboembolic risk.
No takes yet. Share an insight, caveat, or question.
Chesebro et al. (1985) conducted a review in Cardiovascular disease. Antiplatelet drugs was evaluated on Thromboembolic risk. Use of antiplatelet drugs in patients undergoing certain cardiovascular surgical procedures or having rapid progression of atherosclerosis may reduce thromboembolic risk.
Synapse has enriched 10 related papers. Consider them for comparative context: